Neurodegenerative Diseases Clinical Trial
Official title:
Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma: Retrospective Review of an Large Cohort of FDG PET Data
The reason why each specific degenerative disease is characterized by a different FDG PET pattern is still unclear today. There are four main hypotheses proposed to explain this selective vulnerability: 1) Nodal stress, theory according to which the main nodes of specific brain networks undergo wear and tear, 2) trans-neuronal diffusion, theory according to which some toxic agents/proteins or altered propagate along network connections through "Prion-like" mechanisms, 3) trophic failure, in which the interruption of inter-modal connectivity causes the loss of collateral trophic factors, and finally 4) shared vulnerability in which regions also distant from each other are part of a common network which gives a susceptibility uniformly distributed throughout the network. FDG PET provides in-vivo information on the distribution of brain synaptic dysfunction prior to complete neural death, and represents the main in vivo biomarker of neural dysfunction associated with different clinical conditions characterized by neurodegeneration phenomena. For this reason, FDG PET is considered a fundamental approach to shed light on the causes of selective brain vulnerability in various pathological conditions.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Completed |
NCT05788133 -
The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training.
|
N/A | |
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Completed |
NCT03295786 -
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT04265482 -
Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
|
||
Not yet recruiting |
NCT02222779 -
Quantification of Transition Metals
|
N/A | |
Recruiting |
NCT01291550 -
Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples
|
N/A | |
Completed |
NCT01450891 -
Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease
|
N/A | |
Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
Recruiting |
NCT06148233 -
CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging
|
N/A | |
Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
Completed |
NCT06251830 -
Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
|
||
Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
Completed |
NCT03353207 -
Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
|
||
Completed |
NCT05095870 -
Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
|
||
Recruiting |
NCT05784090 -
Correlation Between Melatonin Levels in Different Biological Fluids
|
||
Completed |
NCT02108769 -
Yogic Breathing Changes Salivary Components
|
N/A | |
Recruiting |
NCT05508789 -
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
|
Phase 3 | |
Recruiting |
NCT04820881 -
Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
|
||
Recruiting |
NCT05235802 -
Long-term Follow-up in Severe Traumatic Brain Injury
|